Department of Oncology, National Advisory Unit for Late Effects after Cancer Treatment, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Acta Oncol. 2023 Jan;62(1):80-88. doi: 10.1080/0284186X.2023.2168215. Epub 2023 Jan 30.
Chronic fatigue (CF), substantial fatigue for ≥ six months, can manifest as a late effect (LE) after cancer treatment, and may affect several aspects of life. In a Norwegian cohort of Hodgkin's lymphoma survivors (HLS), more than a decade after contemporary risk-adapted treatment regimens with limited use of radiotherapy (RT), we assessed: (1) Prevalence of, (2) factors associated with (3) and implications of CF on socioeconomic status (SES) and work ability (WA).
HLS treated between 1997-2006, aged 8-49 years at diagnosis, were invited to participate in a population-based cross-sectional study on late effects in 2018-2019. In a mailed questionnaire, HLS responded to a fatigue questionnaire (FQ), work ability score (WAS) and short-form health survey (SF-36). Disease- and treatment data were extracted from hospital records. Factors associated with CF were identified by uni- and multivariate analysis. To study the implications of CF on SES and WA, a multinomial regression analysis was performed.
Invitations were extended to 518 HLS and 298 (58%) responded to FQ, of whom 42% had CF with mean (standard deviation [SD]) physical- and mental fatigue scores of 10.2 (4.3) and 5.5 (2.1) respectively. Median age at survey was 45 years, 47% were females. In multivariate analysis female sex ( = 0.03), lower education ( = 0.03), body mass index ≥30 kg/m ( = 0.04), and an increasing number of comorbidities ( = 0.01) were associated with CF. No association with disease stage, chemotherapy or RT was found. CF was associated with poorer WAS scores at survey ( < 0.001), unemployment ( = 0.03), and receiving disability pension ( = 0.003).
After risk-adapted treatment, CF is still a frequent LE among long-term HLS, without apparent association with disease or treatment-related parameters. CF is associated with reduced WA and SES. As no apparent risk reduction is seen with contemporary treatment, further studies should emphasize etiological factors of CF and treatment to alleviate this common LE.
慢性疲劳(CF)是指持续 6 个月以上的严重疲劳,可作为癌症治疗后的晚期效应(LE)出现,并且可能会影响生活的多个方面。在接受现代风险适应性治疗方案(放疗 RT 应用有限)后的十多年,对挪威霍奇金淋巴瘤幸存者(HLS)队列进行了研究:(1)CF 的患病率,(2)CF 的相关因素,以及(3)CF 对社会经济地位(SES)和工作能力(WA)的影响。
1997 年至 2006 年间治疗的 HLS,诊断时年龄为 8-49 岁,被邀请参加 2018-2019 年的一项关于晚期效应的基于人群的横断面研究。HLS 通过邮寄问卷回答疲劳问卷(FQ)、工作能力评分(WAS)和简明健康调查量表(SF-36)。从医院记录中提取疾病和治疗数据。通过单变量和多变量分析确定与 CF 相关的因素。为了研究 CF 对 SES 和 WA 的影响,进行了多项回归分析。
向 518 名 HLS 发出邀请,其中 298 名(58%)对 FQ 做出了回应,其中 42%的人患有 CF,其体力和精神疲劳平均(标准偏差[SD])得分为 10.2(4.3)和 5.5(2.1)。调查时的中位年龄为 45 岁,47%为女性。在多变量分析中,女性( = 0.03)、教育程度较低( = 0.03)、身体质量指数(BMI)≥30kg/m( = 0.04)和合并症数量增加( = 0.01)与 CF 相关。未发现疾病分期、化疗或 RT 与 CF 相关。CF 与调查时较差的 WAS 评分相关( < 0.001)、失业( = 0.03)和领取残疾抚恤金( = 0.003)。
在适应性治疗后,CF 仍然是 HLS 的一种常见的 LE,与疾病或治疗相关参数无明显关联。CF 与降低的 WA 和 SES 相关。由于现代治疗并未明显降低风险,因此应进一步研究 CF 的病因和治疗方法,以减轻这种常见的 LE。